132 patents
Page 5 of 7
Utility
Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof
4 Feb 21
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided.
Olga AB, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
Filed: 21 Jul 20
Utility
Therapeutic Combinations Comprising ANTI-CD123 Immunoconjugates
28 Jan 21
Therapeutic combinations of immunoconjugates that bind to CD123 (e.g., IMGN632) with BCL-2 inhibitors (e.g., venetoclax), and/or a hypomethylating agent (e.g., azacitidine or decitabine) are provided.
Sharlene ADAMS, Callum M. SLOSS, Patrick ZWEIDLER-MCKAY
Filed: 29 Apr 20
Utility
Conjugates of cysteine engineered antibodies
26 Jan 21
The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an engineered Cys, such as an engineered Cys in the heavy chain CH3 domain, at a position corresponds to the EU/OU numbering position 442 (or C442) on an antibody CBA.
Nicholas C. Yoder, Chen Bai, Michael Louis Miller
Filed: 28 Jun 16
Utility
Methods of preparing cytotoxic benzodiazepine derivatives
26 Jan 21
The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
Filed: 12 Sep 18
Utility
Methods of Preparing Cell-binding Agent-drug Conjugates
30 Dec 20
The present invention provides methods of preparing a cell-binding agent-cytotoxic agent conjugate comprising a cell-binding agent (CysCBA) having one or more unpaired cysteine residues covalently linked to a cytotoxic agent.
Scott A. Hilderbrand, Daniel F. Milano
Filed: 19 Mar 20
Utility
Cytotoxic Benzodiazepine Derivatives
30 Dec 20
The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VI).
Ravi V.J. Chari, Michael Louis Miller, Manami Shizuka
Filed: 14 Jun 20
Utility
Anti-CD123 antibodies and conjugates and derivatives thereof
28 Dec 20
The present invention generally relates to antibodies, antigen-binding fragments thereof, polypeptides, and immunoconjugates that bind to CD123 antigen (the α chain of the interleukine 3 receptor, or IL-3Rα).
Yelena Kovtun, Daniel J. Tavares, Lingyun Rui, Thomas Chittenden
Filed: 30 Jan 20
Utility
Therapeutic Combinations Comprising ANTI-FOLR1 Immunoconjugates
23 Dec 20
Therapeutic combinations of immunoconjugates that bind to FOLR1 (e.g., IMGN853) with anti-VEGF agents (e.g., bevacizumab), a platinum-based agent, and/or doxorubicin are provided.
Jose PONTE, Jan PINKAS, Rodrigo R. RUIZ-SOTO
Filed: 3 Jun 20
Utility
Benzodiazepine Derivatives
23 Dec 20
The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formulae (I), (II) and (III).
Michael Louis Miller, Manami Shizuka, Ravi V.J. Chari
Filed: 26 Dec 18
Utility
Methods of preparing cytotoxic benzodiazepine derivatives
30 Nov 20
The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
Michael Reardon, Richard A. Silva
Filed: 10 Nov 19
Utility
Methods of preparing cytotoxic benzodiazepine derivatives
23 Nov 20
The invention provides novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
Baudouin Gérard, Richard A. Silva, Michael Louis Miller, Manami Shizuka
Filed: 16 Jun 19
Utility
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said
23 Nov 20
The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a non-cleavable linker and the cell-binding agent binds to cells of the selected cell population.
Ravi V. J. Chari, Walter A. Blattler
Filed: 22 Jan 17
Utility
Selective sulfonation of benzodiazepine derivatives
2 Nov 20
The invention relates to novel methods of preparing cell-binding agent-cytotoxic agent conjugates, wherein the cytotoxic agent is an imine-containing cytotoxic agent bearing a maleimide group.
Scott A. Hilderbrand, Benjamin M. Hutchins
Filed: 29 Oct 19
Utility
Methods for preparing antibody-drug conjugates
26 Oct 20
This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent.
Brenda A. Kellogg, Rajeeva Singh, Ravi V. Chari
Filed: 31 Jan 19
Utility
Preparation of Maytansinoid Antibody Conjugates by a One-step Process
21 Oct 20
The invention provides a one-step process for preparing a cell-binding agent cytotoxic agent conjugate comprising contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent and contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent, which provides a linker, in a solution having a pH of about 4 to about 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, free cytotoxic agent, and reaction by-products.
Xinfang Li, Jared M. Worful
Filed: 10 Feb 20
Utility
Antibodies and Assays for Detection of Folate Receptor 1
14 Oct 20
The invention generally relates to antibodies that bind to human folate receptor and diagnostic assays for folate receptor 1-based therapies.
Olga AB, Daniel TAVARES, Julianto SETIADY, Sharron LADD, Christina N. CARRIGAN, Lingyun RUI
Filed: 8 Dec 19
Utility
Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
5 Oct 20
The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I).
Wayne C. Widdison
Filed: 26 Feb 18
Utility
Methods of preparing cytotoxic benzodiazepine derivatives
28 Sep 20
The invention relates to novel methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
Baudouin Gérard, Manami Shizuka, Michael Louis Miller, Richard A. Silva
Filed: 5 Jun 19
Utility
Methods for Detection of Folate Receptor 1 In a Patient Sample
9 Sep 20
The invention generally relates to methods and kits for the detection of human folate receptor 1 in a sample.
Raymond XU, Kerry CULM-MERDEK
Filed: 4 Sep 18
Utility
Folate receptor 1 antibodies and immunoconjugates and uses thereof
24 Aug 20
Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided.
Olga Ab, Daniel Tavares, Lingyun Rui, Gillian Payne, Viktor S. Goldmakher
Filed: 14 Apr 19